David Zhao to Time Factors
This is a "connection" page, showing publications David Zhao has written about Time Factors.
Connection Strength
0.967
-
Zitelny E, Newman N, Zhao D. STEMI during the COVID-19 Pandemic - An Evaluation of Incidence. Cardiovasc Pathol. 2020 Sep - Oct; 48:107232.
Score: 0.127
-
Choi CH, Cheng V, Malaver D, Kon N, Kincaid EH, Gandhi SK, Applegate RJ, Zhao DXM. A comparison of valve-in-valve transcatheter aortic valve replacement in failed stentless versus stented surgical bioprosthetic aortic valves. Catheter Cardiovasc Interv. 2019 05 01; 93(6):1106-1115.
Score: 0.116
-
Gilbert ON, Choi CH, Franzil JL, Caughey M, Qureshi W, Stacey RB, Pu M, Applegate RJ, Gandhi SK, Zhao DXM. Comparison of paravalvular aortic leak characteristics in the Medtronic CoreValve versus Edwards Sapien Valve: Paravalvular aortic leak characteristics. Catheter Cardiovasc Interv. 2018 11 01; 92(5):972-980.
Score: 0.111
-
Drafts BC, Choi CH, Sangal K, Cammarata MW, Applegate RJ, Gandhi SK, Kincaid EH, Kon N, Zhao DX. Comparison of outcomes with surgical cut-down versus percutaneous transfemoral transcatheter aortic valve replacement: TAVR transfemoral access comparisons between surgical cut-down and percutaneous approach. Catheter Cardiovasc Interv. 2018 06; 91(7):1354-1362.
Score: 0.107
-
Lynch DR, Dantzler D, Robbins M, Zhao D. Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis. 2013 May; 35(4):476-82.
Score: 0.078
-
Kasasbeh ES, Parvez B, Huang RL, Hasselblad MM, Glazer MD, Salloum JG, Cleator JH, Zhao DX. Learning curve in transradial cardiac catheterization: procedure-related parameters stratified by operators' transradial volume. J Invasive Cardiol. 2012 Nov; 24(11):599-604.
Score: 0.076
-
Leacche M, Byrne JG, Solenkova NS, Reagan B, Mohamed TI, Fredi JL, Zhao DX. Comparison of 30-day outcomes of coronary artery bypass grafting surgery verus hybrid coronary revascularization stratified by SYNTAX and euroSCORE. J Thorac Cardiovasc Surg. 2013 Apr; 145(4):1004-1012.
Score: 0.073
-
Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures. JACC Cardiovasc Interv. 2008 Oct; 1(5):459-68.
Score: 0.057
-
Huang RL, Donelli A, Byrd J, Mickiewicz MA, Slovis C, Roumie C, Elasy TA, Dittus RS, Speroff T, Disalvo T, Zhao D. Using quality improvement methods to improve door-to-balloon time at an academic medical center. J Invasive Cardiol. 2008 Feb; 20(2):46-52.
Score: 0.054
-
Traverse JH, Henry TD, Pepine CJ, Willerson JT, Chugh A, Yang PC, Zhao DXM, Ellis SG, Forder JR, Perin EC, Penn MS, Hatzopoulos AK, Chambers JC, Baran KW, Raveendran G, Gee AP, Taylor DA, Moyé L, Ebert RF, Simari RD. TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. Circ Res. 2018 02 02; 122(3):479-488.
Score: 0.027
-
Paul TK, Bhatheja S, Panchal HB, Zheng S, Banerjee S, Rao SV, Guzman L, Beohar N, Zhao D, Mehran R, Mukherjee D. Outcomes of Saphenous Vein Graft Intervention With and Without Embolic Protection Device: A Comprehensive Review and Meta-Analysis. Circ Cardiovasc Interv. 2017 Dec; 10(12).
Score: 0.027
-
Puskas JD, Halkos ME, DeRose JJ, Bagiella E, Miller MA, Overbey J, Bonatti J, Srinivas VS, Vesely M, Sutter F, Lynch J, Kirkwood K, Shapiro TA, Boudoulas KD, Crestanello J, Gehrig T, Smith P, Ragosta M, Hoff SJ, Zhao D, Gelijns AC, Szeto WY, Weisz G, Argenziano M, Vassiliades T, Liberman H, Matthai W, Ascheim DD. Hybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease: A Multicenter Observational Study. J Am Coll Cardiol. 2016 07 26; 68(4):356-65.
Score: 0.025
-
Halliday SJ, Hemnes AR, Robbins IM, Pugh ME, Zhao DX, Piana RN, Fong PP, Brittain EL. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. J Heart Lung Transplant. 2015 Mar; 34(3):312-8.
Score: 0.022
-
Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012 Dec 12; 308(22):2380-9.
Score: 0.019
-
Richman S, Gee AP, McKenna DH, Traverse JH, Henry TD, Fisk D, Pepine CJ, Bloom J, Willerson JT, Prater K, Zhao D, Koç JR, Anwaruddin S, Taylor DA, Cogle CR, Moyé LA, Simari RD, Skarlatos SI. Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study. Transfusion. 2012 Oct; 52(10):2225-33.
Score: 0.018
-
Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010; 37(4):412-20.
Score: 0.016
-
Traverse JH, Henry TD, Vaughan DE, Vaughn DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD. Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J. 2009 Sep; 158(3):356-63.
Score: 0.015